Annals of Oncology Advance Access published online on November 17, 2005
Annals of Oncology, doi:10.1093/annonc/mdj077
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Università di Padova, Clinica Chirurgica II, Padova, Italy
* To whom correspondence should be addressed. Background: In patients who underwent radical resection for gastric cancer, we investigate the relative efficacy of combined 5-fluorouracil + adriamycin or epirubicin and methotrexate with leucovorin rescue (FAMTX or FEMTX) compared with a control arm. Patients and methods: This report is a prospective combined analysis of two randomized clinical trials conducted on patients who underwent radical resection for histologically proven adenocarcinoma of the stomach or esophago-gastric junction. Three hundred and ninety-seven untreated patients, 206 from 23 European Organization for Research and Treatment of Cancer (EORTC) institutions and 191 from 16 International Collaborative Cancer Group (ICCG) institutions, were randomized. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method and the treatments were compared for these end-points by means of the log-rank test, retrospectively stratified by trial. Results: In a planned combined analysis of the two trials, no significant differences were found between the treatment and control arms for either DFS (hazards ratio: 0.98, P = 0.87) or OS (hazards ratio: 0.98, P = 0.86). The 5-year OS was 43% in the treatment arm and 44% in the control arm and the 5-year DFS was 41% and 42%, respectively. Conclusion: Neither FAMTX nor FEMTX can be advocated as adjuvant treatment in patients who undergo resection for gastric cancer.
Received June 6, 2005
Revised October 5, 2005
Accepted October 11, 2005
original article
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
D. Nitti 1 *,
J. Wils 2,
J. Guimaraes Dos Santos 3,
G. Fountzilas 4,
P. F. Conte 5,
C. Sava 6,
A. Tres 7,
R. C. Coombes 8,
D. Crivellari 9,
A. Marchet 1,
E. Sanchez 3,
J. M. Bliss 10,
J. Homewood 10,
M. L. Couvreur 11,
E. Hall 10,
B. Baron 11,
E. Woods 8,
M. Emson 8,
E. Van Cutsem 12,
and
M. Lise 1
2 Laurentius Hospital, Roermond, The Netherlands
3 Instituto Portugues de Oncologia, Porto, Portugal
4 Aristotle University of Thessaloniki, Macedonia, Greece
5 University Hospital, Modena, Italy
6 Regional Hospital, Treviso, Italy
7 Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain
8 Charing Cross Hospital, and International Collaborative Cancer Group (ICCG), Imperial College London, UK
9 Centro di Riferimento Oncologico, Aviano, Italy
10 Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK
11 European Organization for Research and Treatment of Cancer (EORTC), Data Center, Brussels, Belgium
12 University Hospital Gasthuisberg, Leuven, Belgium
D. Nitti, E-mail: donato.nitti{at}unipd.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Di Costanzo, S. Gasperoni, L. Manzione, G. Bisagni, R. Labianca, S. Bravi, E. Cortesi, P. Carlini, R. Bracci, S. Tomao, et al. Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC J Natl Cancer Inst, March 19, 2008; 100(6): 388 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wu and J. Ji Adjuvant Chemotherapy for Gastric Cancer or Not: A Dilemma? J Natl Cancer Inst, March 19, 2008; 100(6): 376 - 377. [Full Text] [PDF]
|
|